These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 27507031)

  • 1. [Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system].
    Pellat A; Wislez M; Svrcek M; Hammel P; Afchain P; André T
    Bull Cancer; 2016 Oct; 103(10):880-895. PubMed ID: 27507031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
    Wolin EM
    Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuroendocrine carcinoma of the digestive tract: a literature review].
    Jacob J; Chargari C; Helissey C; Ferrand FR; Ceccaldi B; Le Moulec S; Bauduceau O; Fayolle M; Védrine L
    Rev Med Interne; 2013 Nov; 34(11):700-5. PubMed ID: 23871177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas.
    Koumarianou A; Chatzellis E; Boutzios G; Tsavaris N; Kaltsas G
    Endokrynol Pol; 2013; 64(1):60-72. PubMed ID: 23450449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
    Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
    World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.
    Metro G; Ricciuti B; Chiari R; Baretti M; Falcinelli L; Giannarelli D; Sidoni A; Mountzios G; Crinò L; Bellezza G; Rebonato A; Ferolla P; Toschi L
    Lung Cancer; 2016 May; 95():82-7. PubMed ID: 27040856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine Carcinomas of the Digestive Tract: What Is New?
    Pellat A; Cottereau AS; Terris B; Coriat R
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuroendocrine tumors: analysis of 252 cases].
    Chi YH; Jiang WC; Du F; Sun YK; Song Y; Yang L; Zhou AP; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):67-70. PubMed ID: 23648305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Small cell neuroendocrine carcinoma of the uterine cervix: Report of six cases and a review of the literature].
    Bellefqih S; Khalil J; Mezouri I; Kebdani T; Benjaafar N
    Cancer Radiother; 2014 Jun; 18(3):201-7. PubMed ID: 24656987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
    Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
    Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis.
    Puliafito I; Chillari F; Russo A; Cantale O; Sciacca D; Castorina L; Colarossi C; Franchina T; Vitale MP; Ricciardi GRR; Adamo V; Esposito F; Giuffrida D
    Front Endocrinol (Lausanne); 2023; 14():1065599. PubMed ID: 36793289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
    Hainsworth JD; Spigel DR; Litchy S; Greco FA
    J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of small cell lung cancer.
    Morabito A; Carillio G; Daniele G; Piccirillo MC; Montanino A; Costanzo R; Sandomenico C; Giordano P; Normanno N; Perrone F; Rocco G; Di Maio M
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):257-70. PubMed ID: 24767978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
    Thomas KEH; Voros BA; Boudreaux JP; Thiagarajan R; Woltering EA; Ramirez RA
    Oncologist; 2019 Aug; 24(8):1076-1088. PubMed ID: 30635447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma.
    Terashima T; Morizane C; Hiraoka N; Tsuda H; Tamura T; Shimada Y; Kaneko S; Kushima R; Ueno H; Kondo S; Ikeda M; Okusaka T
    Neuroendocrinology; 2012; 96(4):324-32. PubMed ID: 22572060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy in small-cell lung cancer: where should it go?
    Paumier A; Le Péchoux C
    Lung Cancer; 2010 Aug; 69(2):133-40. PubMed ID: 20605651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy.
    Winther-Larsen A; Hoffmann L; Moeller DS; Khalil AA; Knap MM
    Acta Oncol; 2015; 54(9):1574-81. PubMed ID: 26203924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung and digestive neuroendocrine neoplasms. From WHO classification to biomarker screening: Which perspectives?
    Scoazec JY
    Ann Endocrinol (Paris); 2019 Jun; 80(3):163-165. PubMed ID: 31064659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.
    Nakano K; Takahashi S; Yuasa T; Nishimura N; Mishima Y; Sakajiri S; Yokoyama M; Tsuyama N; Ishikawa Y; Hatake K
    Jpn J Clin Oncol; 2012 Aug; 42(8):697-703. PubMed ID: 22701038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.